These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9353141)

  • 41. A short course of pegylated interferon-alpha in acute HCV hepatitis.
    Calleri G; Cariti G; Gaiottino F; De Rosa FG; Bargiacchi O; Audagnotto S; Quaglia S; De Blasi T; Romano P; Traverso A; Leo G; Carbone R; Del Mastro B; Tinelli M; Caramello P; Di Perri G
    J Viral Hepat; 2007 Feb; 14(2):116-21. PubMed ID: 17244251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of chronic hepatitis C in injecting drug users: 5 years' follow-up.
    Dalgard O; Bjøro K; Hellum K; Myrvang B; Skaug K; Gutigard B; Bell H;
    Eur Addict Res; 2002 Jan; 8(1):45-9. PubMed ID: 11818693
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Interferon-alpha can be used successfully in patients with hepatitis C virus-positive chronic hepatitis who have a psychiatric illness.
    Van Thiel DH; Friedlander L; Molloy PJ; Fagiuoli S; Kania RJ; Caraceni P
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):165-8. PubMed ID: 7712309
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Acute hepatitis C in patients receiving hemodialysis.
    Griveas I; Germanidis G; Visvardis G; Morice Y; Perelson AS; Pawlotsky JM; Papadopoulou D
    Ren Fail; 2007; 29(6):731-6. PubMed ID: 17763169
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of human leucocyte alpha-interferon treatment for chronic hepatitis C virus infection.
    Weiland O; Chen M; Lindh G; Mattsson L; Schvarcz R; Sönnerborg A; Wahl M; Wejstål R; Widell A; Norkrans G
    Scand J Infect Dis; 1995; 27(4):319-24. PubMed ID: 8658063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy.
    Murata M; Furusyo N; Ogawa E; Mitsumoto F; Hiramine S; Ikezaki H; Takayama K; Shimizu M; Toyoda K; Kainuma M; Hayashi J
    J Infect Chemother; 2014 May; 20(5):320-4. PubMed ID: 24477330
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The sustained virologic response of nonresponder hepatitis C virus patients with retreatment.
    Akhan SC; Gurel E; Sayan M
    Indian J Pathol Microbiol; 2011; 54(1):81-4. PubMed ID: 21393883
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Progression of hepatitis C in the haemophiliac population in Ireland, after 30 years of infection in the pre-DAA treatment era.
    Murphy N; O'Mahony B; Flanagan P; Noone D; White B; Bergin C; Norris S; Thornton L;
    Haemophilia; 2017 Sep; 23(5):712-720. PubMed ID: 28752601
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.
    Deterding K; Grüner N; Buggisch P; Wiegand J; Galle PR; Spengler U; Hinrichsen H; Berg T; Potthoff A; Malek N; Großhennig A; Koch A; Diepolder H; Lüth S; Feyerabend S; Jung MC; Rogalska-Taranta M; Schlaphoff V; Cornberg M; Manns MP; Wedemeyer H;
    Lancet Infect Dis; 2013 Jun; 13(6):497-506. PubMed ID: 23523674
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks.
    Reichard O; Foberg U; Frydén A; Mattsson L; Norkrans G; Sönnerborg A; Wejstål R; Yun ZB; Weiland O
    Hepatology; 1994 Feb; 19(2):280-5. PubMed ID: 7507462
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Consensus guidelines for the management of hepatitis C infection.
    Consensus Guidelines Committee for the Management of Hepatitis C Infection
    Saudi Med J; 2003 Jul; 24 Suppl 2():S99-118. PubMed ID: 25121186
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The natural course of hepatitis C virus infection 18 years after an epidemic outbreak of non-A, non-B hepatitis in a plasmapheresis centre.
    Datz C; Cramp M; Haas T; Dietze O; Nitschko H; Froesner G; Muss N; Sandhofer F; Vogel W
    Gut; 1999 Apr; 44(4):563-7. PubMed ID: 10075966
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prevalence of hepatitis C in patients with primary antibody deficiency.
    Webster AD; Brown D; Franz A; Dusheiko G
    Clin Exp Immunol; 1996 Jan; 103(1):5-7. PubMed ID: 8565286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France.
    Lefrère JJ; Loiseau P; Martinot-Peignoux M; Mariotti M; Ravera N; Thauvin M; Marcellin P; Janot C
    Transfusion; 1996 May; 36(5):394-7. PubMed ID: 8693501
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alpha-interferon therapy for non-A, non-B hepatitis transmitted by gammaglobulin replacement therapy.
    Thomson BJ; Doran M; Lever AM; Webster AD
    Lancet; 1987 Mar; 1(8532):539-41. PubMed ID: 2434816
    [TBL] [Abstract][Full Text] [Related]  

  • 56. HCV and hypogammaglobulinemia.
    Sierra FJ; Gil-Aguado A; Echevarria JM; León P; Martin JC; Lavilla P; Garcia Rodriguez MC; Fontan G
    J Hepatol; 1997 May; 26(5):1158-9. PubMed ID: 9186852
    [No Abstract]   [Full Text] [Related]  

  • 57. Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data.
    Yap PL
    Clin Ther; 1996; 18 Suppl B():43-58. PubMed ID: 8930441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment of hypogammaglobulinaemia in chronic lymphocytic leukaemia by low-dose intravenous gammaglobulin.
    Jurlander J; Geisler CH; Hansen MM
    Eur J Haematol; 1994 Aug; 53(2):114-8. PubMed ID: 8088382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Possible transmission of hepatitis C virus infection with intravenous immunoglobulin.
    Schiano TD; Bellary SV; Black M
    Ann Intern Med; 1995 May; 122(10):802-3. PubMed ID: 7717610
    [No Abstract]   [Full Text] [Related]  

  • 60. Spurious outbreak of HCV in bone-marrow recipients treated with cytomegalovirus immunoglobulin.
    Ward KN; Morgan G; Ashworth K; Bremner J; O'Callaghan A; Teo CG
    Lancet; 1992 Nov; 340(8830):1290-1. PubMed ID: 1359345
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.